GlobeNewswire by notified

Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)

Share
  • New clinical data from phase I trial UV1-103, combining UV1 with pembrolizumab in advanced melanoma will be presented

Oslo, September 21 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today that further data from its clinical study on the combination of its universal cancer vaccine, UV1, and the PD-1 checkpoint inhibitor, pembrolizumab, will be disclosed in an oral presentation at the 19th International Congress of the Society for Melanoma Research (SMR) on 18 October 2022.

The presenter will be Dr. Yousef Zakharia, Investigator for the UV1-103 clinical trial. Dr. Zakharia is a Medical Oncologist, Clinical Associate Professor and Director Phase I Program at University of Iowa Hospital and Clinics.

“I am pleased to present the results from the UV1-103 trial to international peers in melanoma research”, said Dr. Yousef Zakharia. Carlos de Sousa, CEO of Ultimovacs added: “As Ultimovacs’ five randomized phase II trials of UV1 continue to mature, there is growing interest in the ability of the vaccine to induce long-lasting, survival-associated immune responses. We are honored to be able to present further data on the clinical activity of UV1.”

Ultimovacs’ presentation is entitled ‘Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Unresectable Melanoma’ and will be given as an oral presentation at the International Congress of the Society for Melanoma Research. Society for Melanoma Research will be online and in-person in Edinburgh, UK, October 17 - 20, 2022. The congress brings together the leaders in the field of basic and translational melanoma research and melanoma clinical trial physicians from around the world.

The presentation will be made available at the Company website on October 18, 2022.

***

About the UV1-103phase I trial in Malignant Melanoma
This US-based Phase I clinical trial is evaluating the Company’s lead candidate, UV1, in combination with PD-1 checkpoint inhibitor, pembrolizumab, as a first-line treatment in patients with metastatic malignant melanoma. The clinical results for the 30 patients enrolled are:

  • Objective response rate (ORR): 57%, complete response rate (CR): 33%
  • Median Progression Free Survival (mPFS): 18.9 months (as measured by iRECIST)
  • Overall survival after 12 months: 87%, overall survival after 24 months: 73%

Patients will continue to be followed for long-term survival. UV1 has demonstrated a good safety profile, and no unexpected safety issues related to UV1 have been observed in this trial.

The U.S. Food and Drug Administration (FDA) granted a dual Fast Track designation for UV1 in combination with checkpoint inhibitors in the treatment of unresectable or metastatic melanoma – either as add-on therapy to pembrolizumab or as add-on therapy to ipilimumab. Ultimovacs is currently evaluating UV1 as add-on therapy to ipilimumab and nivolumab as first-line treatment for unresectable or metastatic melanoma in a Phase II study named INITIUM.

About Ultimovacs
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program in five cancer indications enrolling more than 650 patients, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types, in combination with other immunotherapies, for patients with unmet needs. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021. 

For further information, please see www.ultimovacs.com or contact: 

Carlos de Sousa, CEO 
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507  

Anne Worsøe, Head of Investor Relations
Email: ir@ultimovacs.com
Phone: +47 906 86 815

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com 
Phone: +44 7483 284 853 


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Phoenix Software Delivers a Faster JES3plus® with V1R227.9.2022 13:00:00 CEST | Press release

Phoenix Software releases updates to its product line in September 2022 EL SEGUNDO, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Phoenix Software International, Inc., today announced its intention to make JES3plus V1R2, a derivative work based on IBM’s z/OS® JES3, generally available effective September 30, 2022. This release provides new functionality and integrates continuous delivery items made available over the past twelve months. Thanks to Phoenix’s JES3plus Customer Advisory Council, organizations that migrate to JES3plus can reap the benefits of new features that were ranked in terms of providing true business value to their fellow customers. JES3plus V1R2 Functional Highlights: Parallel SPOOL I/O – Takes full advantage of the Parallel Access Volumes technology supported by modern mainframe DASD through support for up to eight STARTIO channel programs running concurrently for a single SPOOL extent. This is a major improvement over the traditional JES3 approach of allowing only on

Norsk Hydro: Invitation - Hydro's third quarter 2022 results27.9.2022 13:00:00 CEST | Press release

Hydro's third quarter 2022 results will be released at 07:00 CEST (01:00 AM EST, 06:00 GMT), on Tuesday, October 25, 2022. The quarterly report and presentation slides will be available on hydro.com at the same time. Presentation in Oslo Hydro will host an in-person presentation and Q&A, in English, at the Felix Conference Centre at Bryggetorget 3, Oslo, at 08:30 CEST on Tuesday, October 25, 2022. The presentation, by President and CEO Hilde Merete Aasheim and CFO Pål Kildemo, can also be seen on the webcast. To attend the presentation in Oslo, please register your details via this link. There will also be a separate virtual Q&A session at 11:00 CEST. Please register your details using this link to join the conference call. Once registered, you will receive an email containing your dial in number(s) and PINs. Investor contact: Line Haugetraa +4741406376 line.haugetraa@hydro.com

Norsk Hydro: Presentasjon av Hydros resultat for tredje kvartal 202227.9.2022 13:00:00 CEST | Pressemelding

Hydros resultat for tredje kvartal 2022 blir offentliggjort tirsdag 25. oktober 2022 kl. 07.00 CEST (01:00 AM EST, 06:00 GMT). Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på hydro.com. Presentasjon i Oslo Det blir holdt fysisk presentasjon og Q&A ved Felix Konferansesenter på Bryggetorget 3, Oslo, samme dag, kl. 08.30 CEST. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for økonomi og finans Pål Kildemo. Hele presentasjonen kan følges direkte på webcast. For å delta på presentasjonen i Oslo, vennligst registrer dine detaljer via denne lenken. Det vil være også være en separat digital Q&A telefonkonferanse klokken 11:00 CEST. Vennligst benytt denne lenken for å registrere deg til telefonkonferansen. Etter registrering vil du motta en epost med telefonnummer og deltakerkode. Investorkontakt: Line Haugetraa +4741406376 line.haugetraa@hydro.com

Lytho Appoints Geert Bruinink to Lead Operations in Europe27.9.2022 10:00:00 CEST | Press release

Seasoned Executive Brings a Mix of General Management and Sales Leadership as the Company Expands Reach in Europe for its Creative Workflow and Digital Asset Management (DAM) Software AMSTERDAM, the Netherlands and RALEIGH, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Lytho, a creative operations platform providing creative workflow and digital asset management (DAM) tools to brand and creative teams, today announced it has hired Geert Bruinink as its Country Manager based in The Netherlands. He will report to Lytho CEO Douglas Thede and have overall responsibility for the company’s European sales and operations. “Geert brings a proven track record of general management and sales leadership skills to Lytho as we extend our presence in Europe,” said Thede. “We’ve seen strong demand for our software because in-house creative teams have grown, and our tools reduce the natural complexity that comes with that growth. We’re thrilled to welcome Geert as a Lythonian and look forward to his contrib

Conagen unveils commercial production of high-purity non-GMO salidroside27.9.2022 10:00:00 CEST | Press release

Ideal for adaptogen supplement solutions and natural preservatives in food and beverages. Bedford, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal plant Rhodiola rosea (golden root). Its strong antioxidant properties as an adaptogen are associated with reducing inflammation, protecting against oxidative stress in cells, and providing relief from depression, fatigue, and stress. Salidroside has also been used to alleviate high altitude sickness. Unlike other salidroside products currently on the market, Conagen’s salidroside is non-GMO. Conagen leveraged its industry-leading bioconversion technology to produce clean, sustainable salidroside, identical to the compound naturally found in the Rhodiola rosea plant --- the same technology used to produce non-GMO Rebaudioside M, other steviol glycosides, and bitter blockers for sugar reduction solutions w